Cara Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015
SHELTON, Conn., March 19, 2015 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, March 26, 2015, at 4:30 p.m. ET to report fourth quarter and full year 2014 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 1527720. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
Investor Contact Jesse Baumgartner Stern Investor Relations 212-362-1200 jesse@sternir.com Media Contact Annie Starr 6 Degrees 973-415-8838 astarr@6degreespr.com
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
